Understanding ADCs Linker: Advancements in ADC Linkers Development and Their Role with Cytotoxins

Antibody-drug conjugates (ADCs) represent the next frontier in targeted cancer therapies, combining the specificity of monoclonal antibodies with the potency of cytotoxic drugs. One of the most critical components in the construction of effective ADCs is the linker technology, which serves as a bridge between the antibody and the cytotoxin. A deep dive into ADC linkers reveals the complexities behind the development of ADC linkers and their conjugation with cytotoxins, leading to promising advancements in oncology.